Brooklyn Investment Group Invests $28,000 in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Brooklyn Investment Group bought a new stake in Tandem Diabetes Care, Inc. (NASDAQ:TNDM) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 656 shares of the medical device company’s stock, valued at approximately $28,000.

A number of other hedge funds and other institutional investors also recently bought and sold shares of TNDM. Price T Rowe Associates Inc. MD raised its stake in Tandem Diabetes Care by 5.4% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 38,732 shares of the medical device company’s stock worth $1,372,000 after acquiring an additional 1,985 shares in the last quarter. GAMMA Investing LLC lifted its holdings in shares of Tandem Diabetes Care by 11.2% in the 2nd quarter. GAMMA Investing LLC now owns 4,276 shares of the medical device company’s stock valued at $172,000 after purchasing an additional 431 shares during the last quarter. LVW Advisors LLC boosted its position in shares of Tandem Diabetes Care by 15.1% in the 2nd quarter. LVW Advisors LLC now owns 7,869 shares of the medical device company’s stock valued at $317,000 after purchasing an additional 1,034 shares during the period. Diversified Trust Co grew its stake in Tandem Diabetes Care by 11.1% during the 2nd quarter. Diversified Trust Co now owns 14,635 shares of the medical device company’s stock worth $590,000 after buying an additional 1,462 shares during the last quarter. Finally, ORG Partners LLC purchased a new position in Tandem Diabetes Care during the 2nd quarter worth approximately $31,000.

Analyst Upgrades and Downgrades

Several research firms recently commented on TNDM. The Goldman Sachs Group began coverage on shares of Tandem Diabetes Care in a research report on Friday, October 4th. They issued a “neutral” rating and a $46.00 price target for the company. Royal Bank of Canada initiated coverage on Tandem Diabetes Care in a report on Wednesday, October 2nd. They issued an “outperform” rating and a $65.00 target price on the stock. Barclays increased their price target on Tandem Diabetes Care from $58.00 to $60.00 and gave the stock an “overweight” rating in a report on Friday, November 8th. Canaccord Genuity Group lowered their price objective on shares of Tandem Diabetes Care from $57.00 to $56.00 and set a “buy” rating on the stock in a research report on Thursday, November 7th. Finally, Robert W. Baird reduced their target price on shares of Tandem Diabetes Care from $39.00 to $37.00 and set a “neutral” rating for the company in a research note on Thursday, November 7th. Five investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. According to data from MarketBeat, Tandem Diabetes Care has a consensus rating of “Moderate Buy” and an average price target of $54.25.

Tandem Diabetes Care Stock Performance

NASDAQ TNDM opened at $30.63 on Friday. The business has a 50 day moving average price of $34.88 and a 200 day moving average price of $40.79. The company has a market capitalization of $2.01 billion, a P/E ratio of -15.87 and a beta of 1.36. Tandem Diabetes Care, Inc. has a 1-year low of $18.45 and a 1-year high of $53.69. The company has a debt-to-equity ratio of 1.29, a current ratio of 2.90 and a quick ratio of 2.32.

Tandem Diabetes Care (NASDAQ:TNDM) last posted its earnings results on Wednesday, November 6th. The medical device company reported ($0.35) earnings per share for the quarter, beating the consensus estimate of ($0.43) by $0.08. Tandem Diabetes Care had a negative return on equity of 44.19% and a negative net margin of 14.84%. The company had revenue of $243.97 million for the quarter, compared to analyst estimates of $224.14 million. During the same quarter in the prior year, the company earned ($0.38) earnings per share. Tandem Diabetes Care’s revenue was up 31.4% compared to the same quarter last year. Sell-side analysts expect that Tandem Diabetes Care, Inc. will post -1.68 EPS for the current fiscal year.

Insider Buying and Selling at Tandem Diabetes Care

In other news, Director Kim D. Blickenstaff sold 10,000 shares of the stock in a transaction that occurred on Wednesday, November 20th. The shares were sold at an average price of $30.00, for a total value of $300,000.00. Following the sale, the director now directly owns 195,190 shares in the company, valued at $5,855,700. This represents a 4.87 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 2.20% of the stock is currently owned by insiders.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.